Philadelphia Eye Associates

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Jul 29, 2025FDACelebrex — VYSCOXA

May 5, 2020FDACelebrex — ELYXYB

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

1 patent group across drugs · Source: FDA Orange Book

DrugExpires

Celebrex6 patentsMay 27, 2036

Regulatory

Regulatory Timeline

19831 event

FDAOct 19

Ceftin — ZINACEF

Application NDA050558 (NDA)

19851 event

FDAJul 19

Avycaz — FORTAZ

Application NDA050578 (NDA)

19892 events

FDAApr 28

Ceftin — ZINACEF IN PLASTIC CONTAINER

Application NDA050643 (NDA)

FDAApr 28

Avycaz — FORTAZ IN PLASTIC CONTAINER

Application NDA050634 (NDA)

19901 event

FDASep 27

Avycaz — CEPTAZ

Application NDA050646 (NDA)

20011 event

FDAFeb 21

Ceftin — CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

Application NDA050780 (NDA)

20061 event

FDADec 15

Celebrex — CELEBREX

Application NDA020998 (NDA)

20111 event

FDAJun 13

Avycaz — CEFTAZIDIME IN DEXTROSE CONTAINER

Application NDA050823 (NDA)

20201 event

FDAMay 5

Celebrex — ELYXYB

Application NDA212157 (NDA)

20251 event

FDAJul 29

Celebrex — VYSCOXA

Application NDA211759 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)